Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Patrick Flume MD

Patrick A. Flume MD

Distinguished Professor of Medicine and Pediatrics, The Powers-Huggins Chair for Cystic Fibrosis, Medical University of South Carolina, Charleston, South Carolina

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections.

He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis.

He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.

Disclosures

Grant support: AN2, Armata, Boeringher-Ingelheim, Cystic Fibrosis Foundation Therapeutics, Insmed, National Institutes of Health, Paratek, Sound Pharmaceuticals, Inc, Spero

Consultant: AN2, Insmed, Spero, Zambon